Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

19 of 40

Byron Hewett, chairman and CEO of BioBDx

Byron Hewett, chairman and CEO of BioBDx, came to San Francisco this year to network with potential investors at JPM, with hopes to close a new $9 million funding round by the end of March. But there were also plenty of meetings with possible strategic partners that could help expand the reach of the company's diagnostic tool for attention deficit hyperactivity disorder, or ADHD. The 15-minute computer-based test gained 510(k) clearance in 2004, but BioBDx hopes to add a CE marking to its approvals by the end of January. That means the company plans to expand in Europe through 2013, and the extra funding will enable that to happen.